CompBrief BY VELARION

Companies Cidara Therapeutics, Inc.

Cidara Therapeutics CEO salary & total pay, FY2024: $6M

Cidara Therapeutics (CDAR) CEO salary, fiscal 2024: Jeffrey Stein was paid a salary of $617,600 and $5,965,903 in total compensation. Free brief. Every figure links to the company’s own filing.

Velarion Intel: free for 3 days, no card →

Email me Cidara Therapeutics, Inc.’s executive pay brief as a PDF

You get it on this page the moment you ask; press Download and a copy goes to your email too. Every figure is cited to its filing.

After the PDF, up to three short notes on the deeper reports for this company. Reply “unsubscribe” to any of them, any time.

Also free: The Pay Desk, the weekly executive pay briefing.

Jeffrey Stein's complete compensation dossier

A PDF and a CSV sent to your email: Jeffrey Stein's pay in every fiscal year Cidara Therapeutics, Inc. reported it, line by line, with Jeffrey Stein's equity grants and Cidara Therapeutics, Inc.'s disclosed peer group where the company discloses them. Every row is cited to its filing.

One-time report. No refunds.

See an example →
CEO total pay$5,965,903CEO Jeffrey Stein · source
Say-on-pay support74.56%Latest vote · source

CEO pay, last three years

  • $1,558,544FY2023
  • $5,965,903FY2024

CEO total pay was $5,965,903 in fiscal 2024, up from $1,558,544 in fiscal 2023.

FY2024: salary $617,600 · bonus $0 · stock awards $0 · option awards $4,867,353

Executives and directors

Frequently asked questions

Who was the highest-paid executive at Cidara Therapeutics, Inc. in fiscal 2024?
As disclosed, Jeffrey Stein (President and Chief Executive Officer) was the highest-paid executive at Cidara Therapeutics, Inc. in fiscal 2024, with total compensation of $5,965,903.
How did shareholders vote on Cidara Therapeutics, Inc.'s executive compensation?
As disclosed, 74.56% of shareholders supported Cidara Therapeutics, Inc.'s executive compensation in the latest say-on-pay vote.
How much does Cidara Therapeutics, Inc. spend in total on board compensation for fiscal 2024?
As disclosed, Cidara Therapeutics, Inc. reported total board compensation of $422,524 for fiscal 2024.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

Full detail

Every table from the filing. Open any section.

Summary compensation table
Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Jeffrey Stein$617,600$0$0$4,867,353$470,600$0$10,350$5,965,903
President and Chief Executive Officer
Leslie Tari453,500076,1881,276,166224,200010,3502,040,404
Chief Scientific Officer
Taylor Sandison505,100—88,1741,411,6010—10,3502,015,225
Former Chief Medical Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2024 totalFY2023 totalFY2022 totalΔ FY2023→2024
Jeffrey Stein$5,965,903$1,558,544—↑ +4,407,359
Leslie Tari2,040,404———
Taylor Sandison2,015,225884,092—↑ +1,131,133

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

Incentive-plan design — the Compensation Discussion & Analysis

Our compensation program is designed to encourage our management team to achieve our short-term and long-term corporate objectives while effectively managing business risks and challenges. We provide a competitive total compensation package through a combination of base salary, an annual performance-based bonus, and long-term equity-based incentives to align the interests of our employees with those of our stockholders.

CEO STI target (% of salary)—
CEO LTI target (% of salary)—
Independent consultantAon Consulting, Inc.
Clawback policytrue
Anti-hedgingtrue
Anti-pledgingtrue
Equity grants and outstanding awards

No plan-based awards are on file for this fiscal year.

Outstanding equity awards at fiscal year-end 2024

ExecutiveAwardExercisableShares unvestedExercise priceMarket value unvested
Jeffrey SteinOption15,1241,37516.65—
Jeffrey SteinRSU—2,723—73,194
Jeffrey SteinOption15,85511,31920.2—
Jeffrey SteinRSU—9,058—243,479
Jeffrey SteinOption13,00538,99413.7—
Jeffrey SteinOption46,741514,14710.75—
Jeffrey SteinOption10,274—137.2—
Jeffrey SteinOption7,949—197.8—
Jeffrey SteinOption11,000—156—
Jeffrey SteinOption11,749—80—
Jeffrey SteinOption13,249—52.2—
Jeffrey SteinOption16,499—39.6—
Jeffrey SteinOption26,249—51—
Leslie TariOption4,81443516.65—
Leslie TariRSU—867—23,305
Leslie TariOption5,2553,74420.2—
Leslie TariRSU—3,000—80,640
Leslie TariOption2,7868,33813.7—
Leslie TariRSU—5,562—149,507
Leslie TariOption12,519137,70510.75—
Leslie TariOption3,696—49—
Leslie TariOption2,746—49—
Leslie TariOption4,249—39.6—
Leslie TariOption5,999—51—
Leslie TariOption1,499—30.4—
Taylor SandisonOption4,58541416.65—
Taylor SandisonRSU—825—22,176
Taylor SandisonOption5,2503,75020.2—
Taylor SandisonRSU—3,000—80,640
Taylor SandisonOption2,9508,82413.7—
Taylor SandisonRSU—6,437—173,027
Taylor SandisonOption13,903152,93310.75—
Taylor SandisonOption3,499—80—
Taylor SandisonOption3,249—52.2—
Taylor SandisonOption3,094—49—
Taylor SandisonOption202—49—
Taylor SandisonOption7,249—39.6—
Taylor SandisonOption7,249—51—
Director compensation
DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Daniel BurgessIndependent · Audit (Chair) · Nominating and Governance$92,000—$359,511——$451,511
Theodore R. SchroederIndependent · Audit · Compensation and Human Capital (Chair)64,000—359,511——423,511
Chrysa MineoIndependent · Audit · Compensation and Human Capital56,500—334,604——391,104
Carin Canale-TheakstonIndependent · Compensation and Human Capital47,500—284,789——332,289
Bonnie BasslerIndependent · Nominating and Governance (Chair)46,767—284,789——331,556
James MersonIndependent · Nominating and Governance30,189—58,073——88,262
Ryan SpencerIndependent27,444—58,073——85,517
Laura TadvalkarIndependent27,444—58,073——85,517
Timothy R. FransonIndependent17,113—0——17,113
David GollaherIndependent13,567—0——13,567

Board fee structure and ownership guideline

Annual cash retainer$40,000
Annual equity retainer—
Per board meeting fee—
Committee chair fees (audit / comp / nom-gov)20,000 / 15,000 / 10,000
Stock ownership guideline—

Total cost of the board

ComponentFY2024
Cash retainers and fees$422,524
Equity awards (grant-date value)$0
All other compensation$0
Total cost of the board$422,524

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

Peer group, and who names Cidara Therapeutics as a peer

Companies that benchmark against CDAR

1 company names CDAR as a compensation peer

Each company listed discloses CDAR in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named CDAR in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Cidara Therapeutics, Inc.2024Jeffrey Stein$617,600$0$4,867,353$470,600$5,965,903

Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

Say-on-pay history and pay ratio
Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20252025-06-188,077,4702,745,37410,57774.56%Passed
20242024-07-182,174,835155,45213,43993.33%Passed
20232023-06-2225,902,449798,488204,03996.27%Passed
20222022-06-2222,246,8544,142,811216,62983.62%Passed
20212021-06-2324,880,078454,234365,37596.81%Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.

Say-on-pay — history, company’s computation

Meeting yearMeeting dateApproval — company’s computation
20252025-06-1874.56%a
20242024-07-1893.33%b
20232023-06-2296.27%c

a. Approved under the standard stated in the filing — “• To be approved, Proposal 6, the advisory approval of the compensation of our named executive officers, must receive "For" votes from the holders of a majority of shares present by virtual attendance at the Annual Meeting or represented by proxy and entitled to vote on the matter at the virtual Annual Meeting. || Abstentions: Abstentions will have the same effect as "Against" votes.”.

b. Voting standard not stated in the filing.

c. Approved under the standard stated in the filing — “Abstentions will have the same effect as "Against" votes.”.

Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

Insider trades since the proxy

Every insider equity transaction reported on Form 4 after the 2024 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Nicole Negar DavarpanahChief Medical Officer2025-05-01A20,000$0$0Derivative, Class A CommonForm 4 ↗
Nicole Negar DavarpanahChief Medical Officer2025-05-01A10,00000CommonForm 4 ↗
Chrysa MineoDirector2025-06-02A2,2702249,281CommonForm 4 ↗
Chrysa MineoDirector2025-06-03A1,0502324,614CommonForm 4 ↗
Bonnie BasslerDirector2025-06-18A11,10000Derivative, Class A CommonForm 4 ↗
Daniel BurgessDirector2025-06-18A11,10000Derivative, Class A CommonForm 4 ↗
Carin Canale-TheakstonDirector2025-06-18A11,10000Derivative, Class A CommonForm 4 ↗
James MersonDirector2025-06-18A11,10000Derivative, Class A CommonForm 4 ↗
Chrysa MineoDirector2025-06-18A11,10000Derivative, Class A CommonForm 4 ↗
Theodore R. SchroederDirector2025-06-18A11,10000Derivative, Class A CommonForm 4 ↗
Ryan SpencerDirector2025-06-18A11,10000Derivative, Class A CommonForm 4 ↗
Joshua ResnickDirector2025-06-18A5,07900Derivative, Class A CommonForm 4 ↗
RA CAPITAL MANAGEMENT, L.P.Director2025-06-18A5,07900Derivative, Class A CommonForm 4 ↗
RA CAPITAL MANAGEMENT, L.P.Director2025-06-26A2,272,7274499,999,988Common, indirectForm 4 ↗
Nicole Negar DavarpanahChief Medical Officer2025-09-11D4746329,797CommonForm 4 ↗
Nicole Negar DavarpanahChief Medical Officer2025-12-10D10,3322202,268,907CommonForm 4 ↗
Shane WardCOO & CLO2025-12-10D6,45900Derivative, Class A CommonForm 4 ↗
Shane WardCOO & CLO2025-12-10D3,50000Derivative, Class A CommonForm 4 ↗
Shane WardCOO & CLO2025-12-10D9,9592202,191,747CommonForm 4 ↗
Shane WardCOO & CLO2025-12-10A6,45920130,472CommonForm 4 ↗
Shane WardCOO & CLO2025-12-10A3,5001758,289CommonForm 4 ↗
Shane WardCOO & CLO2025-12-10D15,0412203,303,004CommonForm 4 ↗
Frank KarbeChief Financial Officer2025-12-10D7,2902201,600,884CommonForm 4 ↗
Jeffrey SteinDirector2025-12-10D2,285220501,786CommonForm 4 ↗
Jeffrey SteinDirector2025-12-10A33,07200CommonForm 4 ↗
Jeffrey SteinDirector2025-12-10D33,07200CommonForm 4 ↗
Jeffrey SteinDirector2025-12-17A2,24400CommonForm 4 ↗
Jeffrey SteinDirector2025-12-17D2,24400CommonForm 4 ↗
Jeffrey SteinDirector2025-12-19A10,63800CommonForm 4 ↗
Jeffrey SteinDirector2025-12-19D10,63800CommonForm 4 ↗
Jeffrey SteinDirector2025-12-22D5,42500CommonForm 4 ↗
Nicole Negar DavarpanahChief Medical Officer2025-12-29D45000CommonForm 4 ↗
Nicole Negar DavarpanahChief Medical Officer2026-01-07D20,000——Derivative, Class A CommonForm 4 ↗
Nicole Negar DavarpanahChief Medical Officer2026-01-07D30,000——Derivative, Class A CommonForm 4 ↗
Nicole Negar DavarpanahChief Medical Officer2026-01-07D62,597——Derivative, Class A CommonForm 4 ↗
Nicole Negar DavarpanahChief Medical Officer2026-01-07D5,000——Derivative, Class A CommonForm 4 ↗
Nicole Negar DavarpanahChief Medical Officer2026-01-07D11,000——Derivative, Class A CommonForm 4 ↗
Nicole Negar DavarpanahChief Medical Officer2026-01-07D8,333——CommonForm 4 ↗
Nicole Negar DavarpanahChief Medical Officer2026-01-07D12,5532222,780,490CommonForm 4 ↗
Shane WardCOO & CLO2026-01-07D50,000——Derivative, Class A CommonForm 4 ↗
Shane WardCOO & CLO2026-01-07D135,540——Derivative, Class A CommonForm 4 ↗
Shane WardCOO & CLO2026-01-07D12,499——Derivative, Class A CommonForm 4 ↗
Shane WardCOO & CLO2026-01-07D6,207——Derivative, Class A CommonForm 4 ↗
Shane WardCOO & CLO2026-01-07D12,500——Derivative, Class A CommonForm 4 ↗
Shane WardCOO & CLO2026-01-07D25,0832225,555,885CommonForm 4 ↗
Frank KarbeChief Financial Officer2026-01-07D115,000——Derivative, Class A CommonForm 4 ↗
Frank KarbeChief Financial Officer2026-01-07D43,125——CommonForm 4 ↗
Frank KarbeChief Financial Officer2026-01-07D7,5262221,667,009CommonForm 4 ↗
Jeffrey SteinDirector2026-01-07D275,000——Derivative, Class A CommonForm 4 ↗
Jeffrey SteinDirector2026-01-07D560,888——Derivative, Class A CommonForm 4 ↗
Jeffrey SteinDirector2026-01-07D51,999——Derivative, Class A CommonForm 4 ↗
Jeffrey SteinDirector2026-01-07D27,174——Derivative, Class A CommonForm 4 ↗
Jeffrey SteinDirector2026-01-07D16,499——Derivative, Class A CommonForm 4 ↗
Jeffrey SteinDirector2026-01-07D26,249——Derivative, Class A CommonForm 4 ↗
Jeffrey SteinDirector2026-01-07D16,499——Derivative, Class A CommonForm 4 ↗
Jeffrey SteinDirector2026-01-07D13,249——Derivative, Class A CommonForm 4 ↗
Jeffrey SteinDirector2026-01-07D11,749——Derivative, Class A CommonForm 4 ↗
Jeffrey SteinDirector2026-01-07D11,000——Derivative, Class A CommonForm 4 ↗
Jeffrey SteinDirector2026-01-07D7,949——Derivative, Class A CommonForm 4 ↗
Jeffrey SteinDirector2026-01-07D67,49822214,950,807CommonForm 4 ↗
Jeffrey SteinDirector2026-01-07D2,379222526,949CommonForm 4 ↗
Jeffrey SteinDirector2026-01-07D5,7632221,276,505CommonForm 4 ↗
Daniel BurgessDirector2026-01-07D11,100——Derivative, Class A CommonForm 4 ↗
Daniel BurgessDirector2026-01-07D20,500——Derivative, Class A CommonForm 4 ↗
Daniel BurgessDirector2026-01-07D2,125——Derivative, Class A CommonForm 4 ↗
Daniel BurgessDirector2026-01-07D2,125——Derivative, Class A CommonForm 4 ↗
Daniel BurgessDirector2026-01-07D1,400——Derivative, Class A CommonForm 4 ↗
Daniel BurgessDirector2026-01-07D875——Derivative, Class A CommonForm 4 ↗
Daniel BurgessDirector2026-01-07D875——Derivative, Class A CommonForm 4 ↗
Daniel BurgessDirector2026-01-07D550——Derivative, Class A CommonForm 4 ↗
Daniel BurgessDirector2026-01-07D550——Derivative, Class A CommonForm 4 ↗
Daniel BurgessDirector2026-01-07D550——Derivative, Class A CommonForm 4 ↗
Daniel BurgessDirector2026-01-07D450——Derivative, Class A CommonForm 4 ↗
Daniel BurgessDirector2026-01-07D15022233,225CommonForm 4 ↗
Theodore R. SchroederDirector2026-01-07D11,100——Derivative, Class A CommonForm 4 ↗
Theodore R. SchroederDirector2026-01-07D20,500——Derivative, Class A CommonForm 4 ↗
Theodore R. SchroederDirector2026-01-07D2,125——Derivative, Class A CommonForm 4 ↗
Theodore R. SchroederDirector2026-01-07D2,125——Derivative, Class A CommonForm 4 ↗
Theodore R. SchroederDirector2026-01-07D1,400——Derivative, Class A CommonForm 4 ↗
Theodore R. SchroederDirector2026-01-07D875——Derivative, Class A CommonForm 4 ↗
Theodore R. SchroederDirector2026-01-07D875——Derivative, Class A CommonForm 4 ↗
Theodore R. SchroederDirector2026-01-07D550——Derivative, Class A CommonForm 4 ↗
Theodore R. SchroederDirector2026-01-07D550——Derivative, Class A CommonForm 4 ↗
Theodore R. SchroederDirector2026-01-07D550——Derivative, Class A CommonForm 4 ↗
Theodore R. SchroederDirector2026-01-07D450——Derivative, Class A CommonForm 4 ↗
Chrysa MineoDirector2026-01-07D11,100——Derivative, Class A CommonForm 4 ↗
Chrysa MineoDirector2026-01-07D19,000——Derivative, Class A CommonForm 4 ↗
Chrysa MineoDirector2026-01-07D2,125——Derivative, Class A CommonForm 4 ↗
Chrysa MineoDirector2026-01-07D2,125——Derivative, Class A CommonForm 4 ↗
Chrysa MineoDirector2026-01-07D1,400——Derivative, Class A CommonForm 4 ↗
Chrysa MineoDirector2026-01-07D875——Derivative, Class A CommonForm 4 ↗
Chrysa MineoDirector2026-01-07D875——Derivative, Class A CommonForm 4 ↗
Chrysa MineoDirector2026-01-07D550——Derivative, Class A CommonForm 4 ↗
Chrysa MineoDirector2026-01-07D550——Derivative, Class A CommonForm 4 ↗
Chrysa MineoDirector2026-01-07D1,000——Derivative, Class A CommonForm 4 ↗
Chrysa MineoDirector2026-01-07D3,320222735,380CommonForm 4 ↗
Bonnie BasslerDirector2026-01-07D11,100——Derivative, Class A CommonForm 4 ↗
Bonnie BasslerDirector2026-01-07D16,000——Derivative, Class A CommonForm 4 ↗
Bonnie BasslerDirector2026-01-07D2,125——Derivative, Class A CommonForm 4 ↗
Bonnie BasslerDirector2026-01-07D2,125——Derivative, Class A CommonForm 4 ↗
Bonnie BasslerDirector2026-01-07D1,400——Derivative, Class A CommonForm 4 ↗
Bonnie BasslerDirector2026-01-07D875——Derivative, Class A CommonForm 4 ↗
Bonnie BasslerDirector2026-01-07D1,750——Derivative, Class A CommonForm 4 ↗
Bonnie BasslerDirector2026-01-07D152223,323CommonForm 4 ↗
Carin Canale-TheakstonDirector2026-01-07D11,100——Derivative, Class A CommonForm 4 ↗
Carin Canale-TheakstonDirector2026-01-07D16,000——Derivative, Class A CommonForm 4 ↗
Carin Canale-TheakstonDirector2026-01-07D2,125——Derivative, Class A CommonForm 4 ↗
Carin Canale-TheakstonDirector2026-01-07D2,125——Derivative, Class A CommonForm 4 ↗
Carin Canale-TheakstonDirector2026-01-07D1,400——Derivative, Class A CommonForm 4 ↗
Carin Canale-TheakstonDirector2026-01-07D875——Derivative, Class A CommonForm 4 ↗
Carin Canale-TheakstonDirector2026-01-07D1,750——Derivative, Class A CommonForm 4 ↗
James MersonDirector2026-01-07D11,100——Derivative, Class A CommonForm 4 ↗
James MersonDirector2026-01-07D2,125——Derivative, Class A CommonForm 4 ↗
James MersonDirector2026-01-07D4,250——Derivative, Class A CommonForm 4 ↗
Ryan SpencerDirector2026-01-07D11,100——Derivative, Class A CommonForm 4 ↗
Ryan SpencerDirector2026-01-07D2,125——Derivative, Class A CommonForm 4 ↗
Ryan SpencerDirector2026-01-07D4,250——Derivative, Class A CommonForm 4 ↗
Joshua ResnickDirector2026-01-07D5,079——Derivative, Class A CommonForm 4 ↗
Joshua ResnickDirector2026-01-07D22,200——Derivative, Class A CommonForm 4 ↗
RA CAPITAL MANAGEMENT, L.P.Director2026-01-07D89,95615,5051,394,767,780Derivative, Class A CommonForm 4 ↗
RA CAPITAL MANAGEMENT, L.P.Director2026-01-07D1,286,786——Derivative, Class A CommonForm 4 ↗
RA CAPITAL MANAGEMENT, L.P.Director2026-01-07D5,079——Derivative, Class A CommonForm 4 ↗
RA CAPITAL MANAGEMENT, L.P.Director2026-01-07D22,200——Derivative, Class A CommonForm 4 ↗
RA CAPITAL MANAGEMENT, L.P.Director2026-01-07D4,652,3092221,030,486,444Common, indirectForm 4 ↗
RA CAPITAL MANAGEMENT, L.P.Director2026-01-07A1,286,7860129Common, indirectForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

Sources (144 citations)

Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.

  • Section 01, Jeffrey Stein. DEF 14A, filed 2025-04-25. Section “Executive Compensation” · page 35. As printed: 5,965,903. View filing ↗
  • Section 01, Leslie Tari. DEF 14A, filed 2025-04-25. Section “Executive Compensation”. As printed: 2,040,404. View filing ↗
  • Section 01, Taylor Sandison. DEF 14A, filed 2025-04-25. Section “Executive Compensation”. As printed: 2,015,225. View filing ↗
  • Section 08, Daniel Burgess. DEF 14A, filed 2025-04-25. Section “Director Compensation”. As printed: 451,511. View filing ↗
  • Section 08, Theodore R. Schroeder. DEF 14A. Section “Director Compensation”. As printed: 423,511.
  • Section 08, Chrysa Mineo. DEF 14A, filed 2025-04-25. Section “Director Compensation”. As printed: 391,104. View filing ↗
  • Section 08, Carin Canale-Theakston. DEF 14A. Section “Director Compensation”. As printed: 332,289.
  • Section 08, Bonnie Bassler. DEF 14A, filed 2025-04-25. Section “Director Compensation”. As printed: 331,556. View filing ↗
  • Section 08, James Merson. DEF 14A, filed 2025-04-25. Section “Director Compensation”. As printed: 88,262. View filing ↗
  • Section 08, Ryan Spencer. DEF 14A, filed 2025-04-25. Section “Director Compensation”. As printed: 85,517. View filing ↗
  • Section 08, Laura Tadvalkar. DEF 14A, filed 2025-04-25. Section “Director Compensation”. As printed: 85,517. View filing ↗
  • Section 08, Timothy R. Franson. DEF 14A, filed 2025-04-25. Section “Director Compensation”. As printed: 17,113. View filing ↗
  • Section 08, David Gollaher. DEF 14A, filed 2025-04-25. Section “Director Compensation”. As printed: 13,567. View filing ↗
  • Section 02, Nicole Negar Davarpanah 2025-05-01. Form 4, filed 2025-05-12. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Nicole Negar Davarpanah 2025-05-01. Form 4, filed 2025-05-12. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Chrysa Mineo 2025-06-02. Form 4, filed 2025-06-04. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Chrysa Mineo 2025-06-03. Form 4, filed 2025-06-04. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Bonnie Bassler 2025-06-18. Form 4, filed 2025-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Daniel Burgess 2025-06-18. Form 4, filed 2025-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Carin Canale-Theakston 2025-06-18. Form 4, filed 2025-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, James Merson 2025-06-18. Form 4, filed 2025-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Chrysa Mineo 2025-06-18. Form 4, filed 2025-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Theodore R. Schroeder 2025-06-18. Form 4, filed 2025-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Ryan Spencer 2025-06-18. Form 4, filed 2025-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Joshua Resnick 2025-06-18. Form 4, filed 2025-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, RA CAPITAL MANAGEMENT, L.P. 2025-06-18. Form 4, filed 2025-06-18. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, RA CAPITAL MANAGEMENT, L.P. 2025-06-26. Form 4, filed 2025-06-30. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Nicole Negar Davarpanah 2025-09-11. Form 4, filed 2025-09-15. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Nicole Negar Davarpanah 2025-12-10. Form 4, filed 2025-12-12. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Shane Ward 2025-12-10. Form 4, filed 2025-12-12. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Shane Ward 2025-12-10. Form 4, filed 2025-12-12. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Shane Ward 2025-12-10. Form 4, filed 2025-12-12. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Shane Ward 2025-12-10. Form 4, filed 2025-12-12. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Shane Ward 2025-12-10. Form 4, filed 2025-12-12. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Shane Ward 2025-12-10. Form 4, filed 2025-12-12. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Frank Karbe 2025-12-10. Form 4, filed 2025-12-12. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Jeffrey Stein 2025-12-10. Form 4, filed 2025-12-12. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Jeffrey Stein 2025-12-10. Form 4, filed 2025-12-29. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Jeffrey Stein 2025-12-10. Form 4, filed 2025-12-29. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Jeffrey Stein 2025-12-17. Form 4, filed 2025-12-29. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Jeffrey Stein 2025-12-17. Form 4, filed 2025-12-29. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Jeffrey Stein 2025-12-19. Form 4, filed 2025-12-29. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Jeffrey Stein 2025-12-19. Form 4, filed 2025-12-29. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Jeffrey Stein 2025-12-22. Form 4, filed 2025-12-29. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Nicole Negar Davarpanah 2025-12-29. Form 4, filed 2025-12-29. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Nicole Negar Davarpanah 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Nicole Negar Davarpanah 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Nicole Negar Davarpanah 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Nicole Negar Davarpanah 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Nicole Negar Davarpanah 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Nicole Negar Davarpanah 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Nicole Negar Davarpanah 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Shane Ward 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Shane Ward 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Shane Ward 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Shane Ward 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Shane Ward 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Shane Ward 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Frank Karbe 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Frank Karbe 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Frank Karbe 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Jeffrey Stein 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Jeffrey Stein 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Jeffrey Stein 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Jeffrey Stein 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Jeffrey Stein 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Jeffrey Stein 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Jeffrey Stein 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Jeffrey Stein 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Jeffrey Stein 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Jeffrey Stein 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Jeffrey Stein 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Jeffrey Stein 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Jeffrey Stein 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Jeffrey Stein 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Daniel Burgess 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Daniel Burgess 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Daniel Burgess 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Daniel Burgess 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Daniel Burgess 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Daniel Burgess 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Daniel Burgess 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Daniel Burgess 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Daniel Burgess 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Daniel Burgess 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Daniel Burgess 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Daniel Burgess 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Theodore R. Schroeder 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Theodore R. Schroeder 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Theodore R. Schroeder 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Theodore R. Schroeder 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Theodore R. Schroeder 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Theodore R. Schroeder 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Theodore R. Schroeder 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Theodore R. Schroeder 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Theodore R. Schroeder 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Theodore R. Schroeder 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Theodore R. Schroeder 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Chrysa Mineo 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Chrysa Mineo 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Chrysa Mineo 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Chrysa Mineo 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Chrysa Mineo 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Chrysa Mineo 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Chrysa Mineo 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Chrysa Mineo 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Chrysa Mineo 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Chrysa Mineo 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Chrysa Mineo 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Bonnie Bassler 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Bonnie Bassler 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Bonnie Bassler 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Bonnie Bassler 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Bonnie Bassler 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Bonnie Bassler 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Bonnie Bassler 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Bonnie Bassler 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Carin Canale-Theakston 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Carin Canale-Theakston 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Carin Canale-Theakston 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Carin Canale-Theakston 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Carin Canale-Theakston 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Carin Canale-Theakston 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Carin Canale-Theakston 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, James Merson 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, James Merson 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, James Merson 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Ryan Spencer 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Ryan Spencer 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Ryan Spencer 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Joshua Resnick 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Joshua Resnick 2026-01-07. Form 4, filed 2026-01-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, RA CAPITAL MANAGEMENT, L.P. 2026-01-07. Form 4, filed 2026-01-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, RA CAPITAL MANAGEMENT, L.P. 2026-01-07. Form 4, filed 2026-01-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, RA CAPITAL MANAGEMENT, L.P. 2026-01-07. Form 4, filed 2026-01-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, RA CAPITAL MANAGEMENT, L.P. 2026-01-07. Form 4, filed 2026-01-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, RA CAPITAL MANAGEMENT, L.P. 2026-01-07. Form 4, filed 2026-01-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, RA CAPITAL MANAGEMENT, L.P. 2026-01-07. Form 4, filed 2026-01-09. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 06, 2025 vote. Form 8-K, filed 2025-06-20. Item 5.07 · say-on-pay result. As reported: 74.56% (votes for as printed: 8,077,470). View filing ↗
  • Section 06, 2024 vote. Form 8-K, filed 2024-07-18. Item 5.07 · say-on-pay result. As reported: 93.33% (votes for as printed: 2,174,835). View filing ↗
  • Section 06, 2023 vote. Form 8-K, filed 2023-06-23. Item 5.07 · say-on-pay result. As reported: 96.27% (votes for as printed: 25,902,449). View filing ↗
  • Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
  • Section 09b board cost (computed). Computed. Cash 422,524 + equity 0 + all other 0 = 422,524, summed across the director compensation table rows.
  • Cidara Therapeutics, Inc. (subject), Section 10b CEO total. DEF 14A, filed 2025-04-25. CEO total compensation as printed in Cidara Therapeutics, Inc.'s own proxy. As printed: 5,965,903. View filing ↗
Get the full report — $299